Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on GSK3923868 PK in Healthy Participants
NCT06597500Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK3923868 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoints: Area under plasma concentration versus time curve from time zero to last quantifiable concentration at Day 11, Area under plasma concentration versus time curve from time zero to infinity at Day 11 and 2 more. Started Sep 2024; status: completed.
02
Drugs
GSK3923868
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06597500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597500.